March 14, 2024
UPDATE (Jan. 8, 2024): FDA is aware that some providers, including hospital or health-system pharmacies, may be preparing other STS products for patient use in place of […]
March 14, 2024
“Q&A with FDA” provides engaging conversation and discussion about the latest regulatory topics. In this podcast series, FDA’s Division of Drug Information will answer some of […]
March 14, 2024
New data continued to show clinical benefits from continuous glucose monitoring (CGM) in people with type 2 diabetes, including those who don’t use insulin. Use of […]
March 14, 2024
Skipping meals, mood and anxiety disorders, as well as vaping and substance use, all raise the risk for frequent recurrent headaches in children and adolescents, new […]
March 14, 2024
San Diego — In separate studies evaluating treatments for severe forms of alopecia, inhibitors of Janus kinases (JAKs) produced clinically meaningful hair regrowth, according to late-breaking […]
March 14, 2024
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending that patients being treated for visual impairment caused by chronic diabetic […]
March 14, 2024
FDA’s Patient Affairs is responsible for managing the Agency’s Patient Listening Session program. This page contains a list of all the Patient Listening Sessions that have been […]
March 14, 2024
TOPLINE: Topical calcineurin inhibitors (TCIs), topical corticosteroids (TCSs), and topical Janus kinase (JAK) inhibitors are supported as mainstay treatments in new expert recommendations on the use […]
March 14, 2024
On a November morning in 2022, James Messenger opened wide and swallowed a capsule like no other. Messenger was no stranger to taking pills. He’d first […]